Metabolic Pharmaceuticals recruits for obesity drug Phase II-B trial

By Jennifer Chiou

New York, Oct. 18 - Metabolic Pharmaceuticals Ltd announced it is recruiting subjects for a low-dose Phase II-B human clinical trial of its obesity drug, AOD9604, called the Options study.

The study will involve 16 sites in Australia and 480 obese men and women. The last subject is expected to complete the study in early 2007.

"We are delighted that the Phase II-B clinical trial for AOD9604 is commencing on schedule," chief executive officer Roland Scollay said in a news release.

"Given the encouraging trial results we have had to date and the blockbuster potential of this drug, we anticipate substantial local and international interest in the Options study."

The primary aims of the study include weight loss over 12 weeks using daily oral doses of the drug combined with safety and tolerability.

The 32-week study is a randomized, double-blind, placebo-controlled, parallel-group trial.

Metabolic Pharmaceuticals is a biotechnology company based in Melbourne, Australia. It also has development programs aimed neuropathic pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.